Open AccessCyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
Author(s) -
Wen-Yan Peng,
Xue Jiang,
Lei Zhu,
Xiaofeng Li,
QinMei Zhou,
Ying Jin,
Zhipeng You,
Miaoqin Wu,
Xiuming Jin,
Xiaoyi Li,
Shiying Zhou
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s370559
Subject(s) - medicine , clinical endpoint , randomized controlled trial , adverse effect , clinical trial , ophthalmology , surgery
To confirm the efficacy and safety of a novel ophthalmic cyclosporine A gel (CyclAGel, 0.05% CsA) in treating patients with moderate-to-severe dry eye disease (DED).